Quantum Pharmaceuticals
Quantum Pharmaceuticals is a technology based drug discovery company. We develop a unique computational drug discovery platform (QUANTUM), provide drug discovery services, and pursue our own in-house drug discovery projects searching for novel compounds with anti-bacterial, anti-viral and anti-cancer efficacy.
Quantum@linkedin.com
Contacts: office@q-pharm.com or comment any post on the site. You are welcome!Subscription Options:
Categories
- absorbtion (3)
- active transport (2)
- ADME (4)
- albumin (1)
- antibiotics (1)
- antiviral (4)
- bioavailability (3)
- cancer (3)
- cardiotoxicity (1)
- collaboration (13)
- compound libraries (1)
- COPD (1)
- docking (12)
- drug design (4)
- drug discovery platform (1)
- druglikeness (4)
- false postive (3)
- flue (1)
- Generalized Born (15)
- GPCR (1)
- HERG (6)
- HIV (2)
- HIV-1 integrase (1)
- HSV (1)
- human neutrophil elastase (1)
- IC50 (18)
- inflammation (3)
- kinase (1)
- LD50 (2)
- logP (1)
- mechanism of action exploration (2)
- MRDD (3)
- new therapeutic uses (1)
- oncology (4)
- openbabel (3)
- PDK1 (1)
- polar liquid (16)
- publications (10)
- q-Mol (1)
- QSAR (1)
- Quantum Software (10)
- RecA (1)
- scoring (1)
- selectivity (3)
- solvation energy (18)
- ss DNA (1)
- talk (5)
- toxicity (7)
- trombine (2)
- tuberculosis (3)
- Uncategorized (4)
- video (3)
- water (19)
Recent comments
- Talk@MIPT (in Russian) on Video recorded from "Water as a ferroelectric…" presentation at MIPT, November 5th, 2008
- FFT acceleration demonstration for (surface)GB methods on Water polarization charges in Generalized Born models.
- FFT acceleration demonstration for (surface)GB methods on O(N) Surface Charges Generalized Born calculation demonstration
- FFT acceleration demonstration for (surface)GB methods on O(N) SCGB solvation models: first “blood”
- FFT acceleration demonstration for (surface)GB methods on How to use Born surface charges to calculate solvation energy?
tuberculosis Archive
-
Bactericidal activity study of the newest anti-tuberculosis compound QP-42 completed
Posted on June 14, 2010 | View CommentsEvaluation of bactericidal activity (ability to cause the death of the microorganism) of the substance QP42 in vitro was determined in the automated system Bactec MGIT 960. The precipitate the bacterial cells from the tubes, where growth has been identified in the presence of the... -
Quantum tests a novel targeted anti-tuberculosis compound
Posted on June 5, 2010 | View CommentsThe situation with drug resistant forms of tuberculosis (TB), aka MDR and XDR forms, remains increasingly troubling. XDR form was originally identified in 2006 and by now comprising up to 30-50% cases in some regions of South Africa and India. 30% HIV-positive patients with XDR... -
ISTC/NIH-NIAID meeting, Moscow, 17.11.09
Posted on November 17, 2009 | View CommentsAs part of recent efforts to expand cooperation in health, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) is interested in learning more about the spectrum of biomedical research and expertise in the Russian Federation. In particular, efforts focusing on detection of drug...